SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Brivanib

Item No. 23690

CAS Registry No.:	649735-46-6
Formal Name:	(2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol
Synonym:	BMS 540215
MF:	$C_{19}H_{19}FN_4O_3$
FW:	370.4
Purity:	≥95%
UV/Vis.:	λ_{max}: 221, 241 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Brivanib is supplied as a crystalline solid. A stock solution may be made by dissolving the brivanib in the solvent of choice. Brivanib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of brivanib in ethanol is approximately 3 mg/ml and approximately 33 mg/ml in DMSO and DMF.

Brivanib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, brivanib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Brivanib has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Brivanib is an ATP-competitive inhibitor of human vascular endothelial growth factor receptors (VEGFRs) 1 and 2 and fibroblast growth factor receptor 1 (FGFR1; IC_{50}s = 380, 25, and 148 nM, respectively, for the human recombinant proteins).[1] It is selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC_{50}s = >1,900 nM), however, it also inhibits recombinant mouse Flk1 with an IC_{50} value of 89 nM. *In vitro*, brivanib inhibits VEGF- and FGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs) with IC_{50} values of 40 and 276 nM, respectively. *In vivo*, brivanib inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model. Brivanib (25 mg/kg per day for 7 days, p.o.) inhibits bile duct ligation-induced liver fibrosis in mice and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs.[2]

References

1. Bhide, R.S., Cai, Z.W., Zhang, Y.Z., *et al*. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. *J. Med Chem*. **49(7)**, 2143-2146 (2006).
2. Nakamura, I., Zakharia, K., Banini, B.A., *et al*. Brivanib attenuates hepatic fibrosis *in vivo* and stellate cell activation *in vitro* by inhibition of FGF, VEGF and PDGF signaling. *PLoS One* **9(4)**, e92273 (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM